This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AutoZone and National Beverage Corp. highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AutoZone and National Beverage Corp. highlighted as Zacks Bull and Bear of the Day.
CVS Health (CVS) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus
by Zacks Equity Research
Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.
Hologic (HOLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.
Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy
by Zacks Equity Research
Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $70.89, marking a +0.37% move from the previous day.
Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.
Catalent (CTLT) to Advance Oral Drug Development With New Launch
by Zacks Equity Research
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.
Abiomed (ABMD) Reports Positive Data Backing preCARDIA System
by Zacks Equity Research
Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.
5 ROE Stocks to Buy as Q4 Earnings Witness Shaky Start
by Supriyo Bose
CommScope (COMM), Microchip (MCHP), Regeneron (REGN), Bunge (BG) and Hologic (HOLX) are some of the stocks with high ROE to profit as Q4 earnings witness shaky start to the season.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $69.59, moving -0.53% from the previous trading session.
Cardiovascular Systems (CSII) Expands Lithotripsy Technology
by Zacks Equity Research
Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.
Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth
by Zacks Equity Research
Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.